TVGN

Tevogen is a pre-revenue, clinical-stage cell-therapy company whose balance sheet has already crossed into distress. The FY2025 filing shows $0.00 cash and equivalents against $12.6M of total liabilities and just $4.38M of total assets, leaving stockholders' equity at -$8.23M and a liabilities/equity ratio of -1.53x. With operating cash flow of -$12.3M and an accumulated deficit of -$140M, the company is burning cash it does not have. That combination — no cash, negative equity, no product revenue in any year (FY2022–FY2025 revenue is blank) — is the definition of a company that must raise capital imminently or cease operations, and any raise from this position will be steeply dilutive or debt on punitive terms.

The MD&A confirms the profile: a single clinical product, TVGN 489, a CD8+ T-cell therapy that has only completed a Phase 1 proof-of-concept trial for high-risk COVID-19 — a shrinking, commoditized therapeutic market — plus an early 'Tevogen.AI' initiative and a broad but unproven ExacTcell platform. There is no Phase 2/3 program, no partner, no approved product, and no near-term revenue line. R&D spend was actually cut 64.2% to $11.1M, which reads less like disciplined focus and more like a company throttling its only value-creating activity because it is out of money.